The FDA has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25).Click here to read the press release on the GSK website.
Sunday, October 18, 2009
FDA approves Cervarix
The FDA has approved Cervarix, a new cervical cancer vaccine. The current vaccine Gardasil is made by Merck and Cervarix is made by GlaxoSmithKline (GSK).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment